|Mr. Stefan Weber||CEO & Exec. Director||412.47k||N/A||1965|
|Mr. Roberto Galli||VP of Fin.||N/A||N/A||N/A|
|Mr. Marco Caremi||Exec. VP of Bus. Devel.||N/A||N/A||1957|
|Dr. Ravi Anand||Chief Medical Officer||1.01M||N/A||1957|
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.
Newron Pharmaceuticals S.p.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.